Photo by nci from unsplash
Key Points Question Is high body mass index (BMI) a factor associated with a high 21-gene recurrence score in estrogen receptor (ER)–positive, ERBB2-negative (formerly HER2 or HER2/neu) breast cancer, especially… Click to show full abstract
Key Points Question Is high body mass index (BMI) a factor associated with a high 21-gene recurrence score in estrogen receptor (ER)–positive, ERBB2-negative (formerly HER2 or HER2/neu) breast cancer, especially in younger patients (≤45 years) with breast cancer? Findings In this cohort study, 776 women aged 45 years or younger with breast cancer had a weak positive correlation between 21-gene recurrence score and BMI. In these patients, high BMI was associated with a high recurrence score (>20). Meaning The findings of this study suggest that increasing BMI might be associated with a higher genomic risk in younger patients with ER+ERBB2− breast cancer.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!